The board of directors of the Wai Yuen Tong Medicine Holdings Limited announced that based on the preliminary review of the draft unaudited consolidated management accounts of the Group for the six months ended 30 September 2022 and the information currently available to the Board, the Group is expected to record a loss attributable to owners of the parent of not more than approximately HKD 65 million for the six months ended 30 September 2022 as compared with a profit attributable to owners of the parent for the six months ended 30 September 2021 of approximately HKD 14.1 million. Such expected loss is mainly attributable to the combined effect of (i) decrease in fair value gains on investment properties; (ii) impairment losses on property, plant and equipment recorded for the six months ended 30 September 2022, against the reversal of impairment losses on property, plant and equipment recorded for the six months ended 30 September 2021; (iii) increase in fair value losses and impairment losses on financial assets; and (iv) decrease in revenue from property sales in agricultural produce exchange markets in the People's Republic of China (through the Company's listed subsidiary, China Agri-Products Exchange Limited) as compared to that for the corresponding period in 2021.